Nykode Therapeutics AS (CHIX:NYKDo)
kr 18.69 0 (0%) Market Cap: 2.06 Bil Enterprise Value: 666.43 Mil PE Ratio: 0 PB Ratio: 1.28 GF Score: 57/100

Q4 2023 Nykode Therapeutics ASA Earnings Call Transcript

Feb 28, 2024 / 03:00PM GMT
Release Date Price: kr18.69
Operator

Greetings, and welcome to Nykode Therapeutics Q4 2023 financial results presentation. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Michael Engsig, CEO of Nykode. Please go ahead.

Michael Engsig
Nykode Therapeutics ASA - CEO

Thank you very much and to all our participants, a very warm welcome to the Q4 webcast from Micro Therapeutics, and we assume you're all familiar with the forward-looking statements of my code. And on that note, I will move on.

It's my pleasure today to be joined at this, what we call here by my colleagues, Agnete Fredriksen, Chief Business Officer and Co-Founder; Harald Gurvin, our Chief Financial Officer; as well as Klaus Edvardsen, our Chief Development Officer, who will help me guide you through the highlights of the fourth quarter and answer any questions that you may submit in the system.

So Q4 was another very exciting quarter for us with a good, solid progress for the Company, and we expanded the oncology pipeline

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot